James R. Seibold

25.6k citations

158 papers · 8.3k indexed · 2 hit papers · h-index 47

Pathology and Forensic Medicine top 0.05%
- Systemic Sclerosis and Related Diseases 111
- Autoimmune Bullous Skin Diseases 10
Dermatology top 0.1%
- Dermatologic Treatments and Research 31
Pulmonary and Respiratory Medicine top 0.5%
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 40
- Pulmonary Hypertension Research and Treatments 28
Rheumatology top 0.5%
Immunology top 1%
- Mast cells and histamine 19
Epidemiology
- Inflammatory Myopathies and Dermatomyositis 15
Molecular Biology
- Connective Tissue Growth Factor Research 8

Co-authors: Dinesh Khanna Maureen D. Mayes Daniel E. Furst Virginia Steen Thomas A. Medsger Philip J. Clements Janet Pope Christopher P. Denton
Cited by: Pathology and Forensic Medicine Dermatology Pulmonary and Respiratory Medicine
Partner nations: United States United Kingdom Italy

In The Last Decade

James R. Seibold

154 papers receiving 8.0k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2017 Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis
2013 Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study

Peers

Countries citing papers authored by James R. Seibold

Since Specialization

Citations

This map shows the geographic impact of James R. Seibold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James R. Seibold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James R. Seibold more than expected).

Fields of papers citing papers by James R. Seibold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James R. Seibold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James R. Seibold. The network helps show where James R. Seibold may publish in the future.

Co-authorship network

The 25 scholars most cited alongside James R. Seibold, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James R. Seibold Line = papers co-authored together James R. Seibold links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial James R. Seibold,Toby M. Maher,Kristin B. Highland,Shervin Assassi,Arata Azuma,Laura K. Hummers,Ulrich Costabel,Ute von Wangenheim,Veronika Kohlbrenner,Martina Gahlemann,Margarida Alves,Oliver Distler	2020	49
2	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial Dinesh Khanna,Carlo Albera,Aryeh Fischer,Nader Khalidi,Ganesh Raghu,Leland W.K. Chung,Dan Chen,Elena Schiopu,M. Tagliaferri,James R. Seibold,Eduard Gorina	2016	192
3	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) — Report from OMERACT CTD-ILD Working Group Dinesh Khanna,Shikha Mittoo,Rohit Aggarwal,Susanna Proudman,Nicola Dalbeth,Eric L. Matteson,Kevin K. Brown,Kevin Flaherty,Athol U. Wells,James R. Seibold,Vibeke Strand	2015	131
4	Randomized, prospective, placebo‐controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis James R. Seibold,Christopher P. Denton,Daniel E. Furst,Loı̈c Guillevin,Lewis J. Rubin,Athol U. Wells,M Matucci Cerinic,Gabriela Riemekasten,Paul Emery,Harbajan Chadha‐Boreham,Pascal Charef,Sébastiên Roux,C. M. Black	2010	104
5	Discordance between Patient and Physician Assessments of Disease Severity in Systemic Sclerosis Marie Hudson,Ann Impens,Murray Baron,James R. Seibold,Brett D. Thombs,Jennifer Walker,RUSSELL STEELE	2010	28
6	Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis Vijay Bodukam,Ron D. Hays,Paul Maranian,Daniel E. Fürst,James R. Seibold,Ann Impens,Maureen D. Mayes,Philip J. Clements,D. Khanna	2010	65
7	Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design Dinesh Khanna,James R. Seibold,Athol U. Wells,Oliver Distler,Yannick Allanore,Chris Denton,Daniel E. Furst	2010	22
8	Rapidly progressive fatal interstitial lung disease in a patient with systemic sclerosis Kristine Phillips,Cathryn J. Byrne-Dugan,Eric Batterson,James R. Seibold	2009	3
9	A path to the future in scleroderma Oliver Distler,Marco Matucci‐Cerinic,Ulf Müller‐Ladner,James R. Seibold	2008	2
10	Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients Jason C. Cole,Dinesh Khanna,Philip J. Clements,James R. Seibold,Donald P. Tashkin,Harold E. Paulus,Michael R. Irwin,Sarosh J. Motivala,Daniel E. Furst,(unknown)	2006	23
11	SITAXSENTAN, A SELECTIVE ENDOTHELIN-A RECEPTOR ANTAGONIST, IMPROVES EXERCISE CAPACITY IN PULMONARY ARTERIAL HYPERTENSION (PAH) ASSOCIATED WITH CONNECTIVE TISSUE DISEASE (CTD) James R. Seibold,David B. Badesch,Nazzareno Galiè,David Langleben,Robert Naeije,Gérald Simonneau,Robyn J. Barst	2005	6
12	Estrogens and Neuropeptides in Raynaud's Phenomenon Sergio Generini,James R. Seibold,Marco Matucci‐Cerinic	2005	20
13	Recombinant Human Relaxin in the Treatment of Scleroderma James R. Seibold,Joseph H. Korn,Robert W. Simms,Phillip J. Clements,Larry W. Moreland,Maureen D. Mayes,Daniel E. Fürst,Naomi F. Rothfield,Virginia Steen,Michael Weisman,David H. Collier,Fredrick M. Wigley,Peter A. Merkel,Mary Ellen Csuka,Vivien Hsu,Susan Rocco,Mark Erikson,John H. Hannigan,W. Scott Harkonen,Martin E. Sanders	2000	44
14	Rational use of calcium-channel antagonists in Raynaud??s phenomenon Marc G. Sturgill,James R. Seibold	1998	21
15	Effect of Obesity and Feeding on the Growth Hormone (GH) Response to the GH Secretagogue L-692,429 in Young Men¹ Susan E. Kirk,Barry J. Gertz,Stephen H. Schneider,Mark L. Hartman,Suzan S. Pezzoli,Johanna Wittreich,David Krupa,James R. Seibold,Michael O. Thorner	1997	17
16	A Pharmacokinetic—Pharmacodynamic Model of d‐Sotalol Q‐Tc Prolongation During Intravenous Administration to Healthy Subjects Daniel E. Salazar,David R. Much,Peter Nichola,James R. Seibold,Daniel M. Shindler,Peter H. Slugg	1997	15
17	Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. Daniel O. Clegg,James C. Reading,Maureen D. Mayes,James R. Seibold,Cheryl P. Harris,Fredrick M. Wigley,John Ward,Edward J. Pisko,Michael H. Weisman,P. Lee,Larry W. Moreland,Rosemarie Neuner,Eric P. Gall,Philip J. Clements,Jason Spindler,Edward V. Lally	1994	13
18	Pharmacodynamics of MK-0963, a new 5α-reductase inhibitor: Effects on serum androgen concentrations Jules I. Schwartz,Oscar L. Laskin,Carol A Meeter,Patricia M. Patterson,Stephen H. Schneider,Kenneth C. Lasseter,James R. Seibold	1994	1
19	The bioavailability and nonlinear pharmacokinetics of MK‐679 in humans Haiyung Cheng,Jules I. Schwartz,Charles C. Lin,Raju D. Amin,James R. Seibold,Kenneth C. Lasseter,David L. Ebel,Dominick J. Tocco,John Rogers	1994	2
20	Prognostic importance of cardiac arrhythmias in systemic sclerosis William J. Kostis,James R. Seibold,Darya Turkevich,Alfonse T. Masi,Rafael G. Grau,Thomas A. Medsger,Virginia Steen,Philip J. Clements,Lillian Szydlo,William D’Angelo	1988	102

About James R. Seibold

James R. Seibold is a scholar working on Pathology and Forensic Medicine, Dermatology and Pulmonary and Respiratory Medicine, having authored 158 papers that have together received 8.3k indexed citations. Recurring topics across this work include Systemic Sclerosis and Related Diseases (111 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (40 papers), Dermatologic Treatments and Research (31 papers), Pulmonary Hypertension Research and Treatments (28 papers), Mast cells and histamine (19 papers), Inflammatory Myopathies and Dermatomyositis (15 papers), Autoimmune Bullous Skin Diseases (10 papers) and Connective Tissue Growth Factor Research (8 papers). The work is most often cited by research in Pathology and Forensic Medicine (5.5k citations), Dermatology (2.2k citations) and Pulmonary and Respiratory Medicine (2.9k citations). James R. Seibold has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Dinesh Khanna, Maureen D. Mayes, Daniel E. Furst, Virginia Steen, Thomas A. Medsger, Philip J. Clements, Janet Pope, Christopher P. Denton, Peter A. Merkel and Marco Matucci‐Cerinic.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact